Clinical Trial Update: XIENCE PRIME Japan Post-Marketing Surveillance (PMS)

View source ↗

Summary

Post-marketing surveillance update for XIENCE PRIME in Japan; study completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina
• Coronary Artery Disease
• Coronary Artery Stenosis
• Coronary Occlusion
• Myocardial Ischemia

Drugs mentioned

• Xience Prime (everolimus-eluting stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Angina, Coronary Occlusion | Status: COMPLETED | Results posted: 2016-07-19